Kaposi Sarcoma-Associated Herpesvirus and Staphylococcus aureus Coinfection in Oral Cavities of HIV-Positive Patients: A Unique Niche for Oncogenic Virus Lytic Reactivation.
Adult
Aged
Cell Line
Coinfection
/ microbiology
Female
HIV Infections
/ microbiology
Herpesviridae Infections
/ microbiology
Herpesvirus 8, Human
/ genetics
Humans
Male
MicroRNAs
/ genetics
Middle Aged
Mouth
/ microbiology
Oncogenic Viruses
/ genetics
Sarcoma, Kaposi
/ virology
Staphylococcus aureus
/ pathogenicity
Virus Activation
/ physiology
Virus Latency
/ physiology
Virus Replication
/ genetics
Young Adult
Staphylococcus aureus
HIV
KSHV
Kaposi sarcoma
microRNA
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 03 2020
28 03 2020
Historique:
received:
06
02
2019
accepted:
09
05
2019
pubmed:
22
5
2019
medline:
23
1
2021
entrez:
22
5
2019
Statut:
ppublish
Résumé
Collectively, viruses are the principal cause of cancers arising in patients with immune dysfunction, including human immunodeficiency virus (HIV)-positive patients. Kaposi sarcoma (KS) etiologically linked to Kaposi sarcoma-associated herpesvirus (KSHV) continues to be the most common AIDS-associated tumor. The involvement of the oral cavity represents one of the most common clinical manifestations of this tumor. HIV infection incurs an increased risk among individuals with periodontal diseases and oral carriage of a variety of pathogenic bacteria. However, whether interactions involving periodontal bacteria and oncogenic viruses in the local environment facilitate replication or maintenance of these viruses in the oral cavity of HIV-positive patients remain largely unknown. We previously showed that pathogen-associated molecular patterns (PAMPs) from specific periodontal bacteria promoted KSHV entry into oral cells and subsequent establishment of latency. In the current study, we demonstrate that Staphylococcus aureus, one of common pathogens causing infection in HIV-positive patients, and its PAMPs can effectively induce KSHV lytic reactivation from infected oral cells, through the Toll-like receptor reactive oxygen species and cyclin D1-Dicer-viral microRNA axis. This investigation provides further clinical evidence about the relevance of coinfection due to these 2 pathogens in the oral cavities of a cohort HIV-positive patients and reveals novel mechanisms through which these coinfecting pathogens potentially promote virus-associated cancer development in the unique niche of immunocompromised patients.
Identifiants
pubmed: 31111897
pii: 5491269
doi: 10.1093/infdis/jiz249
pmc: PMC7325796
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1331-1341Subventions
Organisme : NCI NIH HHS
ID : R01 CA228166
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
N Engl J Med. 2000 Apr 6;342(14):1027-38
pubmed: 10749966
Cancer. 2004 Jul 15;101(2):317-24
pubmed: 15241829
PLoS Pathog. 2010 Jan 29;6(1):e1000742
pubmed: 20126446
Oncogene. 2018 Aug;37(33):4534-4545
pubmed: 29743595
Oncol Lett. 2016 Nov;12(5):3537-3542
pubmed: 27900033
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8683-8
pubmed: 19429708
J Int Acad Periodontol. 2010 Oct;12(4):98-103
pubmed: 21128527
ISME J. 2012 Jun;6(6):1176-85
pubmed: 22170420
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Dec;96(6):701-10
pubmed: 14676761
Cell Host Microbe. 2009 Dec 17;6(6):570-5
pubmed: 20006845
J Immunol Methods. 2010 Apr 30;356(1-2):39-46
pubmed: 20211626
Am J Infect Control. 2019 Mar;47(3):323-333
pubmed: 30170767
Int J Cancer. 2008 Jul 1;123(1):187-94
pubmed: 18435450
Cell Microbiol. 2010 Dec;12(12):1746-64
pubmed: 20642807
J Virol. 2013 Feb;87(3):1733-49
pubmed: 23175375
J Virol. 2011 Jan;85(2):715-24
pubmed: 21068240
J Clin Microbiol. 2006 Jul;44(7):2409-15
pubmed: 16825357
Nat Cell Biol. 2010 Feb;12(2):193-9
pubmed: 20081837
Infect Drug Resist. 2010;3:73-86
pubmed: 21694896
J Med Microbiol. 2013 Oct;62(Pt 10):1592-1600
pubmed: 23800598
AIDS. 2017 Sep 24;31(15):2077-2084
pubmed: 28723706
Arch Oral Biol. 2012 Jun;57(6):654-62
pubmed: 22261034
Trends Microbiol. 2017 Aug;25(8):648-661
pubmed: 28259385
PLoS Biol. 2016 Nov 28;14(11):e2000998
pubmed: 27893764
Cell Res. 2011 May;21(5):793-806
pubmed: 21221132
N Engl J Med. 2007 Sep 27;357(13):1352-3
pubmed: 17898112
Anaerobe. 1997 Apr-Jun;3(2-3):97-102
pubmed: 16887570
Periodontol 2000. 2010 Jun;53:89-110
pubmed: 20403107
Physiol Rev. 2007 Jan;87(1):245-313
pubmed: 17237347
Dev Cell. 2016 Nov 21;39(4):452-465
pubmed: 27818180
Oral Dis. 2011 Jan;17(1):13-25
pubmed: 21029260
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
Microbiol Immunol. 1992;36(5):545-50
pubmed: 1513269
J Virol. 2014 Apr;88(8):4466-79
pubmed: 24501407
J Cutan Pathol. 2005 Jan;32(1):21-7
pubmed: 15660651
Nat Commun. 2013;4:2812
pubmed: 24287487
Free Radic Biol Med. 2002 Feb 1;32(3):268-77
pubmed: 11827752
Lancet. 2000 Dec 23-30;356(9248):2160
pubmed: 11191549
Int J Cell Biol. 2012;2012:603961
pubmed: 22505930
J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):233-8
pubmed: 15076237
PLoS One. 2014 Jun 27;9(6):e101326
pubmed: 24971655
Clin Infect Dis. 2001 Oct 15;33(8):1412-6
pubmed: 11565083
Cancer Treat Rev. 2006 Oct;32(6):445-55
pubmed: 16860939
Bull World Health Organ. 2005 Sep;83(9):700-6
pubmed: 16211162
Br J Cancer. 2011 Nov 22;105(11):1768-71
pubmed: 21952625
J Dent Res. 2011 Oct;90(10):1164-70
pubmed: 21471325
N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536
pubmed: 18234764
Eur J Clin Microbiol Infect Dis. 1992 Nov;11(11):985-9
pubmed: 1295767
Nat Rev Cancer. 2010 Oct;10(10):707-19
pubmed: 20865011
PLoS Pathog. 2014 Jul 10;10(7):e1004154
pubmed: 25010730